IDAHO FALLS, Idaho, Nov. 10 /PRNewswire-FirstCall/ -- International
Isotopes Inc. (OTC Bulletin Board: INIS) announces the successful conclusion
of a private placement. The private placement was completed amongst 11
directors, past investors, and major shareholders and totals just over $2
million.

International Isotopes Inc. successfully completed a private placement
with certain shareholders on November 7, 2008. Under the private placement,
the Company offered 8,200,000 Units, each Unit included one share of common
stock priced at $0.25 per common share, and one warrant to purchase another
share of common stock for $.30. At the time the placement was priced, the
offering price was higher than the quoted bid price of the Company's common
stock. The total amount raised from the private placement was $2,050,000,
which is the single largest capital raise by the Company since 1999. All of
the issued shares will be unregistered securities. The offering was entirely
led by the Company, and there were no selling commissions or fees paid by the
Company, other than standard legal expenses for document preparation, in
connection with the offering.

The majority of net proceeds from the private placement will be used to
support engineering design and licensing of the Company's planned uranium
processing and fluorine extraction facility.

Steve T. Laflin, Chief Executive Officer stated, "We are very pleased with
the level and amount of participation of our shareholders in the private
placement, especially in light of today's current market conditions. I
believe their strong participation confirms the significance of the strategic
business direction the Company is taking in regard to utilizing our exclusive
fluoride extraction patent technology and plans for commercial processing of
depleted uranium tails. That process will produce important economic and
environmentally friendly products with the fluoride extracted from depleted
uranium.

Laflin added, "I would like to thank those shareholders for their
participation and their continued support of the Company. The Company will
need to raise significant additional capital to build this project in a couple
years and, given current market conditions, there can be no guarantee the
capital will be available, or available under acceptable terms. The Company
is currently evaluating several paths to raise the needed capital. It is clear
the funds from this private placement allow the timetable for the project to
remain intact, including our design and licensing schedule, for at least the
next year while we explore certain paths and wait for an improvement in market
conditions."

About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine
calibration and reference standards, high purity fluoride gases, and a variety
of cobalt-60 products such as teletherapy sources. The Company also provides
a wide selection of radioisotopes and radiochemicals for medical devices,
calibration, clinical research, life sciences, and industrial applications and
provides a host of analytical, measurement, recycling, and processing services
on a contract basis to clients.

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, including the statements with
respect to the Company's goals with respect to constructing a depleted uranium
de-conversion processing and fluorine extraction facility. Information
contained in such forward-looking statements is based on current expectations
and is subject to change. These statements involve a number of risks,
uncertainties and other factors that could cause actual results, performance
or achievements of International Isotopes Inc. to be materially different from
any future results, performance or achievements expressed or implied by these
forward-looking statements. Other factors, which could materially affect such
forward-looking statements, can be found in International Isotopes Inc.'s
filings with the Securities and Exchange Commission at www.sec.gov, including
our annual report on Form 10-KSB for the year ending December 31, 2007.
Investors, potential investors and other readers are urged to consider these
factors carefully in evaluating the forward-looking statements and are
cautioned not to place undue reliance on such forward-looking statements.
Additional factors that could materially affect the results, performance or
achievements of the Company include the ability to successfully obtain
additional funding necessary to complete its planned de-conversion facility
and complete construction and licensing of such facility, which may not occur.
Achievement by the Company of the project is substantially dependent on
success in securing off-take agreements with commercial enrichment companies
for depleted uranium hexafluoride for de-conversion services and supply of the
raw material for the production of high quality fluoride gasses. The
forward-looking statements made herein are only made as of the date of this
press release and International Isotopes, Inc. undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent events
or circumstances.

SOURCE International Isotopes Inc.